BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 31506740)

  • 1. 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.
    Gawlitza AL; Speith J; Rinke J; Sajzew R; Müller EK; Schäfer V; Hochhaus A; Ernst T
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2835-2843. PubMed ID: 31506740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
    Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
    Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
    Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
    Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
    Ørskov AD; Treppendahl MB; Skovbo A; Holm MS; Friis LS; Hokland M; Grønbæk K
    Oncotarget; 2015 Apr; 6(11):9612-26. PubMed ID: 25823822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
    Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
    Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Wei Y; Zheng H; Lockyer PP; Darbaniyan F; Li Z; Kanagal-Shamanna R; Soltysiak KA; Yang H; Ganan-Gomez I; Montalban-Bravo G; Chien KS; Do KA; Daver N; Garcia-Manero G
    Leuk Lymphoma; 2022 Dec; 63(13):3154-3164. PubMed ID: 36059252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms.
    Schmelz K; Sattler N; Wagner M; Lübbert M; Dörken B; Tamm I
    Leukemia; 2005 Jan; 19(1):103-11. PubMed ID: 15510208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.
    Shirahata-Adachi M; Iriyama C; Tomita A; Suzuki Y; Shimada K; Kiyoi H
    Leuk Res; 2017 Dec; 63():90-97. PubMed ID: 29127861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome.
    Asano M; Ohyashiki JH; Kobayashi-Kawana C; Umezu T; Imanishi S; Azuma K; Akahane D; Fujimoto H; Ito Y; Ohyashiki K
    Drug Des Devel Ther; 2019; 13():1821-1833. PubMed ID: 31239639
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.
    Laille E; Shi T; Garcia-Manero G; Cogle CR; Gore SD; Hetzer J; Kumar K; Skikne B; MacBeth KJ
    PLoS One; 2015; 10(8):e0135520. PubMed ID: 26296092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of EZH2 expression in myelodysplastic syndromes.
    Cabrero M; Wei Y; Yang H; Ganan-Gomez I; Bohannan Z; Colla S; Marchesini M; Bravo GM; Takahashi K; Bueso-Ramos C; Garcia-Manero G
    Leuk Res; 2016 May; 44():1-7. PubMed ID: 26970171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies.
    Orsini P; Impera L; Parciante E; Cumbo C; Minervini CF; Minervini A; Zagaria A; Anelli L; Coccaro N; Casieri P; Tota G; Brunetti C; Ricco A; Carluccio P; Specchia G; Albano F
    Diagn Pathol; 2018 Dec; 13(1):98. PubMed ID: 30579366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
    Cabezón M; Malinverni R; Bargay J; Xicoy B; Marcé S; Garrido A; Tormo M; Arenillas L; Coll R; Borras J; Jiménez MJ; Hoyos M; Valcárcel D; Escoda L; Vall-Llovera F; Garcia A; Font LL; Rámila E; Buschbeck M; Zamora L;
    Clin Epigenetics; 2021 Jan; 13(1):9. PubMed ID: 33446256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression.
    Kazachenka A; Young GR; Attig J; Kordella C; Lamprianidou E; Zoulia E; Vrachiolias G; Papoutselis M; Bernard E; Papaemmanuil E; Kotsianidis I; Kassiotis G
    Genome Med; 2019 Dec; 11(1):86. PubMed ID: 31870430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.
    Tibes R; Al-Kali A; Oliver GR; Delman DH; Hansen N; Bhagavatula K; Mohan J; Rakhshan F; Wood T; Foran JM; Mesa RA; Bogenberger JM
    J Hematol Oncol; 2015 Oct; 8():114. PubMed ID: 26483188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.
    Merlevede J; Droin N; Qin T; Meldi K; Yoshida K; Morabito M; Chautard E; Auboeuf D; Fenaux P; Braun T; Itzykson R; de Botton S; Quesnel B; Commes T; Jourdan E; Vainchenker W; Bernard O; Pata-Merci N; Solier S; Gayevskiy V; Dinger ME; Cowley MJ; Selimoglu-Buet D; Meyer V; Artiguenave F; Deleuze JF; Preudhomme C; Stratton MR; Alexandrov LB; Padron E; Ogawa S; Koscielny S; Figueroa M; Solary E
    Nat Commun; 2016 Feb; 7():10767. PubMed ID: 26908133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy.
    Karoopongse E; Yeung C; Byon J; Ramakrishnan A; Holman ZJ; Jiang PY; Yu Q; Deeg HJ; Marcondes AM
    PLoS One; 2014; 9(9):e107817. PubMed ID: 25225797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
    Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
    Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review and meta
    Kunacheewa C; Thongthang P; Ungprasert P; Utchariyaprasit E; Owattanapanich W
    Hematology; 2019 Dec; 24(1):498-506. PubMed ID: 31221030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.